Huang Juan, Mutti Donald O, Jones-Jordan Lisa A, Walline Jeffrey J
The Ohio State University College of Optometry, Columbus, Ohio *
Optom Vis Sci. 2019 May;96(5):335-344. doi: 10.1097/OPX.0000000000001378.
The Bifocal & Atropine in Myopia (BAM) study aims to determine whether combining 0.01% atropine and +2.50-diopter add center-distance soft bifocal contact lenses (SBCL) slows myopia progression more than SBCL alone. The results could provide significant information on the myopia control effect of combining optical and pharmacological treatments.
This article describes the subject characteristics at baseline, the study methods, and the short-term effects of this combination treatment on visual acuity (VA) and vision-related outcomes.
Subjects from the BAM study who met the baseline eligibility criteria were dispensed the combination treatment for 2 weeks to determine final eligibility. Outcome measures included VA at near and distance (Bailey-Lovie logMAR charts), near phoria (modified Thorington), accommodative lag (Grand Seiko WAM-5500), and pupil size (NeurOptics VIP-200 Pupillometer). Compliance was monitored using surveys. Two subgroups in the Bifocal Lenses In Nearsighted Kids study, single-vision contact lens wearers and those who wore +2.50-diopter add SBCL, will serve as the age-matched historical controls for BAM study.
Forty-nine BAM subjects (9.6 ± 1.4 years) were enrolled; mean spherical equivalent cycloplegic autorefraction was -2.33 ± 1.03 diopters. After 2 weeks of treatment, the best-corrected low-contrast (10% Michelson) distance VA was reduced (pre-treatment, +0.09 ± 0.07; post-treatment, +0.16 ± 0.08; P < .0001), but the high-contrast VA at near or distance was unaffected. Near phoria increased by approximately 2 in the exo direction (P = .01), but the accommodative lag was unchanged. The pupil size was not significantly different between pre-treatment and post-treatment of either the photopic or mesopic condition. Surveys indicated that the subjects wore SBCL 77 ± 22% of waking hours and used atropine 6.4 ± 0.7 days per week.
Two weeks of combination treatment reduced low-contrast distance VA and increased near exophoria slightly, but the subjects were compliant and tolerated the treatment well.
双焦点与阿托品治疗近视(BAM)研究旨在确定0.01%阿托品与+2.50屈光度附加中心距离软性双焦点隐形眼镜(SBCL)联合使用是否比单独使用SBCL更能减缓近视进展。研究结果可为联合光学和药物治疗的近视控制效果提供重要信息。
本文描述了基线时的受试者特征、研究方法以及这种联合治疗对视力(VA)和视力相关结果的短期影响。
从BAM研究中符合基线入选标准的受试者开始接受联合治疗2周,以确定最终入选资格。结果测量包括近距和远距视力(贝利-洛维对数最小分辨角视力表)、近距隐斜(改良索林顿法)、调节滞后(精工WAM-5500)和瞳孔大小(NeurOptics VIP-200瞳孔计)。通过调查问卷监测依从性。近视儿童双焦点镜片研究中的两个亚组,即单焦点隐形眼镜佩戴者和佩戴+2.50屈光度附加SBCL的人,将作为BAM研究的年龄匹配历史对照。
49名BAM受试者(9.6±1.4岁)入组;平均球镜等效睫状肌麻痹自动验光为-2.33±1.03屈光度。治疗2周后,最佳矫正低对比度(10%迈克尔逊)远距视力下降(治疗前,+0.09±0.07;治疗后,+0.16±0.08;P<.0001),但近距或远距高对比度视力未受影响。近距隐斜在外斜方向增加约2(P=.01),但调节滞后未改变。明视或 mesopic条件下治疗前后瞳孔大小无显著差异。调查问卷显示,受试者在清醒时间的77±22%佩戴SBCL,每周使用阿托品6.4±0.7天。
两周的联合治疗降低了低对比度远距视力,并使近距外隐斜略有增加,但受试者依从性良好且对治疗耐受性良好。